Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma

By sjmartinez • January 13, 2025

Talukder R, Bakaloudi DR, Makrakis D, Diamantopoulos LN, Enright T, Leary JB, Raychaudhuri R, Tripathi N, Agarwal N, Jindal T, Brown JR, Zakharia Y, Rey-Cárdenas M, Castellano D, Nguyen CB, Alva A, Zakopoulou R, Bamias A, Barrera RM, Marmolejo D, Drakaki A, Pinato DJ, Korolewicz J, Buznego LA, Duran I, Carballeira CC, McKay RR, Stewart TF, Gupta S, Barata P, Yu EY, Koshkin VS, Khaki AR, Grivas P. Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2024 Dec 2;23(1):102284. doi: 10.1016/j.clgc.2024.102284. Epub ahead of print. PMID: 39798390.

Tags: Biomarker, Bladder cancer, Hematology/Oncology, immunotherapy, Publications, tumor microenvironment

Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial

Powles TB, Van der Heijden MS, Loriot Y, Bedke J, Valderrama BP, Iyer G, Kikuchi E, Hoffman-Censits J, Vulsteke C, Drakaki A, Rausch S, Arafat[...]

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study

García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez[...]

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Frimodt-Møller[...]